Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Emraclidine in Hepatic Impairment
NCT05935033Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of emraclidine in schizophrenia (4 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) at Day 7, Maximum Observed Unbound Plasma Concentration (Cmax,u) at Day 7 and 4 more. Started Jun 2023; status: completed.
02
Drugs
emraclidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05935033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05935033.